Literature DB >> 26407907

Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.

Haibo Wang1, Shengfang Ge2, Guanxiang Qian2, Wei Li3, Jiuwei Cui3, Guanjun Wang3, Andrew R Hoffman4, Ji-Fan Hu5.   

Abstract

The insulin-like growth factor II (IGF2) gene is aberrantly expressed in tumors as a result of loss of imprinting (LOI). Reactivation of the normally-suppressed maternal allele may lead to IGF2 upregulation and increased tumor growth, particularly in colon cancer. However, the mechanisms underlying IGF2 LOI in tumors are poorly defined. In this report, we identified polycomb repressive complex 2 (PRC2) docking factor SUZ12 as a critical factor in regulating IGF2 imprinting in tumors. Human colon cancer cell lines (HRT18 and HT29) show loss of IGF2 imprinting. Ectopic expression of SUZ12 restored normal monoallelic expression of IGF2 in these two colon cancer cell lines. Using chromatin immunoprecipitation (ChIP) and chromatin conformation capture (3C), we found that the virally-expressed SUZ12 bound to IGF2 promoters, coordinating with endogenous CTCF to orchestrate a long range intrachromosomal loop between the imprinting control region (ICR) and the IGF2 promoters. The histone methyltransferase EZH2 was recruited to the IGF2 promoters, where it induced H3K27 hypermethylation, suppressing one allele, leading to the restoration of IGF2 imprinting. These data demonstrate that SUZ12 is a key molecule in the regulation of monoallelic expression of IGF2, suggesting a novel epigenetic therapeutic strategy for modulating IGF2 production in human tumors.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CTCF; Epigenetics; Histone K27 methylation; IGF2 imprinting; Intrachromosomal loop; Polycomb repressive complex 2; Promoter; SUZ12

Mesh:

Substances:

Year:  2015        PMID: 26407907     DOI: 10.1016/j.yexcr.2015.09.016

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms.

Authors:  C Unger; N Kramer; D Unterleuthner; M Scherzer; A Burian; A Rudisch; M Stadler; M Schlederer; D Lenhardt; A Riedl; S Walter; A Wernitznig; L Kenner; M Hengstschläger; J Schüler; W Sommergruber; H Dolznig
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 2.  Insulin Receptor Isoforms in Physiology and Disease: An Updated View.

Authors:  Antonino Belfiore; Roberta Malaguarnera; Veronica Vella; Michael C Lawrence; Laura Sciacca; Francesco Frasca; Andrea Morrione; Riccardo Vigneri
Journal:  Endocr Rev       Date:  2017-10-01       Impact factor: 19.871

3.  Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.

Authors:  Stefan Küffer; Tobias Gutting; Djeda Belharazem; Christian Sauer; Maurice S Michel; Alexander Marx; Lutz Trojan; Philipp Ströbel
Journal:  Mol Oncol       Date:  2018-01-04       Impact factor: 6.603

4.  Germline large genomic alterations on 7q in patients with multiple primary cancers.

Authors:  R A R Villacis; T R Basso; L M Canto; A F Nóbrega; M I Achatz; S R Rogatto
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

5.  CRISPR Cas9-guided chromatin immunoprecipitation identifies miR483 as an epigenetic modulator of IGF2 imprinting in tumors.

Authors:  Yiqun Zhang; Ji-Fan Hu; Hong Wang; Jiuwei Cui; Sujun Gao; Andrew R Hoffman; Wei Li
Journal:  Oncotarget       Date:  2017-05-23

6.  Targeting the IGF1R Pathway in Breast Cancer Using Antisense lncRNA-Mediated Promoter cis Competition.

Authors:  Lingling Pian; Xue Wen; Lihua Kang; Zhaozhi Li; Yuanyuan Nie; Zhonghua Du; Dehai Yu; Lei Zhou; Lin Jia; Naifei Chen; Dan Li; Songling Zhang; Wei Li; Andrew R Hoffman; Jingnan Sun; Jiuwei Cui; Ji-Fan Hu
Journal:  Mol Ther Nucleic Acids       Date:  2018-05-03       Impact factor: 8.886

Review 7.  Dysregulation of ncRNAs located at the DLK1‑DIO3 imprinted domain: involvement in urological cancers.

Authors:  Jiangfeng Li; Haixiang Shen; Haiyun Xie; Yufan Ying; Ke Jin; Huaqing Yan; Song Wang; Mingjie Xu; Xiao Wang; Xin Xu; Liping Xie
Journal:  Cancer Manag Res       Date:  2019-01-15       Impact factor: 3.989

8.  Profiling the long noncoding RNA interaction network in the regulatory elements of target genes by chromatin in situ reverse transcription sequencing.

Authors:  Shilin Zhang; Yichen Wang; Lin Jia; Xue Wen; Zhonghua Du; Cong Wang; Yajing Hao; Dehai Yu; Lei Zhou; Naifei Chen; Jingcheng Chen; Huiling Chen; Hui Zhang; Ilkay Celik; Günhan Gülsoy; Jianjun Luo; Baoming Qin; Xueling Cui; Zhonghui Liu; Songling Zhang; Miguel A Esteban; Ferhat Ay; Wei Xu; Runsheng Chen; Wei Li; Andrew R Hoffman; Ji-Fan Hu; Jiuwei Cui
Journal:  Genome Res       Date:  2019-07-17       Impact factor: 9.043

9.  Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.

Authors:  Undraga Schagdarsurengin; Angela Lammert; Natalie Schunk; Diana Sheridan; Stefan Gattenloehner; Klaus Steger; Florian Wagenlehner; Temuujin Dansranjavin
Journal:  Cell Commun Signal       Date:  2017-10-10       Impact factor: 5.712

Review 10.  LncRNA Functions as a New Emerging Epigenetic Factor in Determining the Fate of Stem Cells.

Authors:  Jingcheng Chen; Yizhuo Wang; Cong Wang; Ji-Fan Hu; Wei Li
Journal:  Front Genet       Date:  2020-03-31       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.